West John Stephen
Known title: President and CEOCIK: 0001779811
Associated companies
Transaction History
| PSNL | ▲ Buy | Option Exercise | 10,000 | $24K | 12/14/2022 | View on chart |
| PSNL | ▲ Buy | Grant | 230,000 | $0 | 8/15/2022 | View on chart |
| PSNL | ▼ Sell | Open Market | 2,408 | $12K | 5/16/2022 | View on chart |
| PSNL | ▲ Buy | Option Exercise | 45,061 | $83K | 4/20/2022 | View on chart |
| PSNL | ▲ Buy | Option Exercise | 64,430 | $119K | 4/13/2022 | View on chart |
| PSNL | ▼ Sell | Open Market | 64,430 | — | 4/13/2022 | View on chart |
| PSNL | ▲ Buy | Grant | 54,347 | $100K | 3/17/2022 | View on chart |
| PSNL | ▲ Buy | Grant | 68,162 | $125K | 3/15/2022 | View on chart |
| PSNL | ▼ Sell | Other | 68,162 | $509K | 3/15/2022 | View on chart |
| PSNL | ▲ Buy | Grant | 21,206 | $39K | 3/14/2022 | View on chart |
| PSNL | ▼ Sell | Other | 21,206 | $173K | 3/14/2022 | View on chart |
| PSNL | ▼ Sell | Other | 10,888 | $98K | 3/11/2022 | View on chart |
| PSNL | ▼ Sell | Other | 32,897 | $309K | 3/10/2022 | View on chart |
| PSNL | ▼ Sell | Open Market | 64,503 | $710K | 1/19/2022 | View on chart |
| PSNL | ▼ Sell | Open Market | 35,484 | $416K | 1/18/2022 | View on chart |
| PSNL | ▼ Sell | Open Market | 2,732 | $35K | 12/17/2021 | View on chart |
| PSNL | ▼ Sell | Open Market | 97,268 | $1.3M | 12/16/2021 | View on chart |
| PSNL | ▼ Sell | Open Market | 100,000 | $1.4M | 11/30/2021 | View on chart |
| PSNL | ▼ Sell | Open Market | 2,348 | $40K | 11/17/2021 | View on chart |
| PSNL | ▼ Sell | Open Market | 100,000 | $1.9M | 10/12/2021 | View on chart |
| PSNL | ▼ Sell | Other | 93,400 | $2.0M | 9/14/2021 | View on chart |
| PSNL | ▼ Sell | Other | 6,600 | $147K | 9/14/2021 | View on chart |
| PSNL | ▲ Buy | Grant | 77,272 | $34K | 8/26/2021 | View on chart |
| PSNL | ▲ Buy | Grant | 115,228 | $51K | 8/19/2021 | View on chart |
| PSNL | ▼ Sell | Other | 115,228 | $1.9M | 8/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Competitors Tempus and Natera draw market attention
Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.
Competitors Tempus and Natera draw market attention. Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.